Why is there such a difference in European PD-L1 test adoption? | Diaceutics

Why is there such a difference in European PD-L1 test adoption?

March 13th, 2017



Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In our February 2017 webinar we discuss the adoption of PD-L1 testing in Europe using Germany and Italy as examples, to understand how different environments can generate different adoption rates, and look at how the process could be optimized.

The PD-L1 testing market is dynamic with 3 new entities, 6 indications, 14+ approvals and 3+ tests all in 3 years, so it’s clear that PD-L1 is going to play a major role in the biomarker and diagnostic landscape. The Diaceutics PM Readiness Report 2016 found that around 40 per cent of all NSCLC trials, regardless of the phase (I-IV), require determination of PD-L1 status:

  • PD-L1 status is combined with other actionable NSCLC biomarkers in half of all Phase II/III NSCLC trials.
  • PD-L1 integration will lead to complex interpretation of trial outcomes.
  • All competitors are exploring the value of combining PD-L1 with known NSCLC biomarkers.

As with all test adoption there are barriers on the route to diagnostic enablement and these can cause problems such as patient leakage, loss of post-market data integrity, erosion of coverage and, ultimately, reduced profit. But as we have demonstrated before, the barriers can vary in different markets.

For instance, Europe can be viewed as one market but individual European countries may encounter different diagnostic enablement barriers. The webinar looks closely at Germany and Italy to highlight this predicament. One example concerns the restricted availability of antibodies:

  • In Germany there are 10 different antibody clones available for testing, but early harmonization, driven by pathologists, made the choice of antibodies easier, with heavy adoption of one antibody.
  • In Italy there are 4 different antibody clones available for testing but there is still a lack of consensus as to which should be used, and harmonization studies started later than in Germany.

The webinar goes on to discuss how a combination of barriers can reduce therapeutic opportunity and dramatically reveals how much one of these countries has lost in both revenue and treatment opportunities.

 

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn